Castellví I, et al. - A retrospective multicenter observational study was designed to examine the safety and effectiveness of abatacept (ABA) given in routine care to patients with systemic sclerosis (SSc). This study included SSc treated individuals with ABA. Researchers obtained 27 patients' data with SSc (93% females; 67% limited SSc).Epidemiological data and clinical outcomes were collected. First, the frequency of adverse effects was evaluated. Secondly, during ABA treatment, they compared the evolution of different organ manifestations. The results of this study indicate that ABA revealed a good safety profile and appears to have some efficacy on joint involvement and related disability in SSc patients treated in routine care.